Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in Q4 2024, with gross profit growth accelerating to 49.7%. The company ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Please go ahead. Thank you, Jason. Good afternoon and welcome to Tempus' Fourth Quarter 2024 Conference Call. This afternoon Tempus released results for the quarter and year ended December 31 ...

16:52 EST Tempus AI (TEM) down 7% at $64.83 after Q4 earnings miss and guidance See what stocks are receiving strong buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

Tempus is expected to releases its 2024 fiscal-year fourth-quarter earnings report after the market closes. Analysts estimate a loss per share of 20 cents and revenue of $203.12 million. Get 5 ...

These speculations have surged in the past month after her investment in AI healthcare firm Tempus AI (NASDAQ:TEM) surged over 300% since 14th January. According to the latest periodic transaction ...

Institutional Interest in Tempus is Still Strong At the end of 2024, Cathie Wood’s ARK Invest increased its stake in TEM by 132% by adding 3.14 million shares. Jane Street Group raised its stake ...

Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...